{"preliminary_commentary":{"by_channel":{"x_thread":33,"youtube":20,"podcast":20},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04658862\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SunRISe-2","nct_id":"NCT04658862","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunrise-2-nct04658862. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SunRISe-2","arms":[{"description":"Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with intravenous (IV) Cetrelimab.","label":"TAR-200 + Cetrelimab","type":"EXPERIMENTAL"},{"description":"Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray \\[Gy\\], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.","label":"Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Urinary Bladder Neoplasms"],"enrollment":{"count":518,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cetrelimab","otherNames":["JNJ-63723283"],"type":"BIOLOGICAL"},{"name":"TAR-200","otherNames":["JNJ-17000139"],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Conventional radiation therapy","otherNames":[],"type":"RADIATION"},{"name":"Hypo-fractioned radiation therapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event","timeFrame":"Up to 8 years"}],"references":[],"start_date":{"date":"2020-12-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","url":"https://clinicaltrials.gov/study/NCT04658862"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunrise-2-nct04658862"}